Emblaveo: When Can It Treat Resistant Abdominal

Who can receive Emblaveo for resistant abdominal infections?

The CDC's account of COVID-19 and antimicrobial resistance provides the backdrop: resistant hospital-onset infections and associated deaths each increased by at least 15% between 2019 and 2020 across seven pathogens. Those figures describe an earlier pandemic period, rather than a new October announcement. They help explain the continuing clinical need for medicines that can treat infections when established antibiotics fail. [CDC overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/COVID-19.html).

Emblaveo combines aztreonam with avibactam. Its February 2025 FDA approval covers adults aged 18 and older with complicated intra-abdominal infections and limited or no alternatives, including infections involving specified susceptible Gram-negative bacteria such as Escherichia coli and Klebsiella pneumoniae. It is administered intravenously alongside metronidazole. This is a defined treatment role: approval does not establish that everyone with an antibiotic-resistant infection should receive it. [Approval announcement and indication](https://news.abbvie.com/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options).

How does aztreonam–avibactam overcome antibiotic resistance?

Some bacteria make multiple enzymes that disable antibiotics. Aztreonam can withstand enzymes called metallo-beta-lactamases, but other enzymes produced by the same organism may still destroy it. Avibactam blocks several of those accompanying enzymes. Pairing the medicines can therefore restore aztreonam's activity against certain bacteria carrying overlapping resistance mechanisms. This complementary action explains the combination's value; it does not mean that avibactam itself blocks metallo-beta-lactamases. [Drug mechanism explained in the approval announcement](https://news.abbvie.com/2025-02-07-U-S-FDA-Approves-EMBLAVEO-TM-aztreonam-and-avibactam-for-the-Treatment-of-Adults-With-Complicated-Intra-Abdominal-Infections-With-Limited-or-No-Treatment-Options).

That protection has limits. Bacteria can remain resistant through other enzymes, changes in antibiotic targets, or mechanisms that reduce drug entry or increase its removal. Culture and susceptibility results should guide treatment when available. A laboratory report describing resistance to one antibiotic does not automatically establish susceptibility to Emblaveo. [U.S. prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a).

What did the REVISIT trial show about treatment benefits?

The randomized, open-label phase 3 REVISIT trial enrolled 422 adults with complicated intra-abdominal infections or hospital-acquired pneumonia, including ventilator-associated pneumonia. Among participants with abdominal infections, clinical cure occurred in 159 of 208 patients receiving aztreonam–avibactam, or 76.4%, compared with 77 of 104 receiving meropenem-based treatment, or 74.0%. Metronidazole accompanied aztreonam–avibactam for abdominal infections. The publication appeared online in October 2024 and in The Lancet Infectious Diseases in February 2025. [REVISIT trial](https://doi.org/10.1016/S1473-3099(24)00499-7).

These results need careful interpretation. REVISIT was descriptive: the small numerical difference does not demonstrate that the combination is superior, and similar percentages alone do not establish equivalence. Participants were enrolled for serious Gram-negative infections rather than exclusively for infections involving the hardest-to-treat resistance mechanisms. Consequently, the overall results cannot supply a precise success rate for every resistant organism encountered in practice. [REVISIT study design and findings](https://doi.org/10.1016/S1473-3099(24)00499-7).

The U.S. label explicitly states that approval rests on limited clinical safety and efficacy data. Treatment also requires attention to kidney function, which affects dosing, and risks including allergic reactions, liver enzyme elevations, serious skin reactions, and Clostridioides difficile-associated diarrhea. These considerations help clinicians assess whether the expected benefit justifies treatment for an individual patient. [U.S. prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=be1a6c99-d4b3-46d7-9e99-6e5f9fab556a).